As part of this partnership, Affidea has implemented Skin Analytics’ DERM, an AI medical device software for the automated analysis of skin lesions. The initial implementation of DERM began in Romania ...

The latest milestone follows PathAI’s 510(k) clearance for AISight Dx, the first FDA-approved digital pathology system.

Please provide your email address to receive an email when new articles are posted on . Twelve-month data from a large U.S. registry study confirmed the clinical utility and high negative predicative ...

Dr Geng discusses his research from AAAAI Annual Meeting, which explored the relationship between atopic dermatitis and comorbid atopic conditions.

In January, after the DermaSensor became the first artificial intelligence (AI)-enabled device cleared by the US Food and Drug Administration (FDA) to evaluate lesions suggestive of skin cancer, the ...

Devices used in combination with medical therapy can improve treatment of acne lesions and even help patients see quicker ...

DERM is an artificial intelligence (AI)-based skin lesion analysis technology intended for use in the screening, triage and assessment of suspected skin cancer lesions in people aged 18 or over. DERM ...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that ...

“Ultraviolet light (whether by natural sunlight or indoor tanning beds) will increase your risk for skin cancer, and simply protecting your skin from UV exposure, including regular use of daily ...

Experience the GentleMax Pro Plus ® Difference Visit Fargo Dermatology and discover the transformative power of GentleMax Pro Plus ®. Whether you’re looking to achieve smoother skin, reduce signs of ...

The diagnostics advisory committee considered evidence on Deep Ensemble for Recognition of Malignancy (DERM) to assess and triage skin lesions referred to the urgent suspected skin cancer pathway from ...